Analyzing MeiraGTx (MGTX) and Momenta Pharmaceuticals (NASDAQ:MNTA)

Momenta Pharmaceuticals ( NASDAQ:MNTA ) and MeiraGTx ( NASDAQ:MGTX ) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, dividends, earnings, institutional ownership and profitability.


This table compares Momenta Pharmaceuticals and MeiraGTx’s net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Momenta Pharmaceuticals -158.21% -44.72% -34.10% MeiraGTx N/A -291.76% -94.04% Analyst Ratings

This is a breakdown of recent recommendations for Momenta Pharmaceuticals and MeiraGTx, as provided by MarketBeat. Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Momenta Pharmaceuticals 0 2 2 0 2.50 MeiraGTx 0 0 4 0 3.00 Momenta Pharmaceuticals presently has a consensus target price of $30.00, indicating a potential upside of 146.71%. MeiraGTx has a consensus target price of $23.67, indicating a potential upside of 135.49%. Given Momenta Pharmaceuticals’ higher possible upside, equities analysts plainly believe Momenta Pharmaceuticals is more favorable than MeiraGTx.

Institutional & Insider Ownership

76.4% of Momenta Pharmaceuticals shares are owned by institutional investors. Comparatively, 22.7% of MeiraGTx shares are owned by institutional investors. 3.7% of Momenta Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Momenta Pharmaceuticals and MeiraGTx’s gross revenue, earnings per share (EPS) and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Momenta Pharmaceuticals $138.88 million 8.62 -$88.09 million ($1.20) -10.13 MeiraGTx N/A N/A -$31.04 million N/A N/A MeiraGTx has lower revenue, but higher earnings than Momenta Pharmaceuticals.


Momenta Pharmaceuticals beats MeiraGTx on 6 of the 10 factors compared between the two stocks.

About Momenta Pharmaceuticals Momenta Pharmaceuticals logo Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company’s complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE. Its biosimilars programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn’s disease, ulcerative colitis, and psoriasis; and M834, a biosimilar of ORENCIA for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis, as well as other biosimilar candidates. The company’s novel therapeutics programs include M254, a hyper-sialylated version of intravenous immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy; M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; and M230, a recombinant trivalent human IgG1 Fc multimer to block tissue damage mediated by immune complexes. It has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.

About MeiraGTx MeiraGTx logo MeiraGTx Holdings plc, an integrated clinical stage gene therapy company, develops various gene therapy products for the lives of patients suffering from acquired and inherited disorders. The company focuses on various areas of unmet medical need comprising inherited retinal diseases, xerostomia, and neurodegenerative diseases. It has four ongoing clinical programs, including AAV-RPE65, which is in Phase I/II clinical trials for the treatment of RPE65-deficiency in adult and pediatric patients; AAV-RPGR that is in Phase I/II clinical trials to treat x-linked retinitis pigmentosa in adult and pediatric patients; AAV-CNGB3 that is in Phase I/II clinical trials for the treatment of achromatopsia in adult and pediatric patients; and AAV-AQP1, which is in Phase I/II clinical trials for the treatment of patients with grade 2 or 3 radiation-induced xerostomia. The company also has a pipeline of preclinical and research programs in other indications. MeiraGTx Holdings plc has a research collaboration and evaluation agreement with Janssen Pharmaceuticals, Inc. the company was founded in 2015 and is based in New York, New York.

Receive News & Ratings for Momenta Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Momenta Pharmaceuticals and related companies with’s FREE daily email newsletter .

Click Here to Continue...

Add a Comment

Your email address will not be published. Required fields are marked *